DARPA-SN-26-65 The Defense Advanced Research Projects Agency (DARPA), through its Information Innovation Office (I2O), has released a Special Notice titled Decentralized Artificial Intelligence through Controlled Emergence (DICE), DARPA-SN-26-65. This notice reflects DARPA’s ongoing mandate to pursue bold, high-impact research that delivers asymmetric advantages for national defense. With DICE, DARPA is targeting one of the most
DARPA’s DICE Program Read More »
DOWNLOAD THE SOLICITATION ARPA-H’s new Technology InteGrator and AcceleratoR (TIGAR) Innovative Solutions Opening (ISO) is a tightly scoped opportunity for government contractors and their research partners to reshape how complex biologics, tissues, and organs are stored, transported, and deployed at scale. By seeding high-risk, high-impact biopreservation concepts, TIGAR aims to unlock temperature-flexible storage for increasingly
ARPA-H TIGAR Opens a New Lane for Biopreservation Innovation Read More »
BARDA_FY23 Modernized BAA Solicitation – Amendment 7 The Biomedical Advanced Research and Development Authority (BARDA) has released its modernized Broad Agency Announcement (BAA-23-100-SOL-00004, Amendment 7), creating a flexible, multi-year pathway for industry to partner with the U.S. Government on advanced medical countermeasures (MCMs) for CBRN, pandemic influenza, and emerging infectious disease threats to the U.S.
BARDA’s Modernized BAA: A New On-Ramp for Advanced Medical Countermeasure Development Read More »
RRPV-26-10-RAPID The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a new Request for Project Proposals (RPP) to stand up U.S.-based rapid antibody and protein binder production platforms that can go from pathogen gene sequence to immunoassay-ready reagents within weeks instead of months. This is a targeted opportunity to position platform
BARDA’s RRPV 26-10-RAPID Solicitation for Rapid Antibody Production Read More »
DARPA-SN-26-61 Overview of Solicitation Hemorrhage remains one of the leading causes of preventable death on the battlefield, with existing countermeasures often falling short in their transition from laboratory research to clinical and commercial application. In response, the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) has released a Request for Information (RFI) under
DARPA Hemorrhage Countermeasures RFI Read More »
STOMP_ISO_ARPA-H-SOL-26-152 The Advanced Research Projects Agency for Health (ARPA-H) has released an Innovative Solutions Opening (ISO) for the Systematic Targeting of Microplastics (STOMP) program, signaling a major federal investment in understanding and addressing the health impacts of micro- and nano-plastics (MNPs). As mounting evidence links MNP exposure to a range of adverse health outcomes, ARPA-H
ARPA-H STOMP Program: Advancing the Science of Microplastics and Human Health Read More »
DARPA_ERIS_Announcement-_R9_1_April_2026 A New Front Door for Disruptive Defense Technology The Defense Advanced Research Projects Agency (DARPA), in partnership with its marketplace manager, the Applied Research Institute (ARI), has launched the Expedited Research Innovation System (ERIS), a long-term open call intended to accelerate the discovery and acquisition of novel technologies relevant to U.S. national security. DARPA
DARPA’s ERIS Initiative Opens a New Pathway for Breakthrough Defense Innovation Read More »
The Medical Chemical, Biological, Radiological, and Nuclear Defense Consortium (MCDC), managed by Advanced Technology International (ATI), has issued a Request for Information (RFI) focused on “Host-Directed Medical Countermeasures.” This effort, led in support of the Capability Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), represents an early step toward shaping a
MCDC’s Host-Directed Therapeutics Initiative Read More »
The Medical CBRN Defense Consortium (MCDC), through Advanced Technology International (ATI), has issued a Request for Information (RFI) on behalf of the Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) for “Prophylaxis in Advanced Development.” This notice is intended strictly for information gathering and planning and does not constitute a Request
The White House’s Genesis Mission, first announced in 2025, represents a foundational shift in how the federal government approaches science, engineering, and advanced technology systems at scale. While the initial announcement positioned the mission as a national call to action, its real significance has become clearer over time. Genesis is less a standalone initiative and
1-CURE_ISO_ARPA-H-SOL-26-147 Cancer remains one of the leading causes of death globally, with existing treatment modalities often limited by cost, accessibility, and effectiveness, particularly for metastatic disease. In response, the Advanced Research Projects Agency for Health (ARPA-H) has released an Innovative Solutions Opening (ISO) under solicitation ARPA-H-SOL-26-147 for the One Comprehensive Universal Radiotherapy for Everyone (1-CURE)
ARPA-H’s 1-CURE Initiative to Revolutionize Universal Cancer Radiotherapy Read More »
ARPA-H-SOL-26-153+DRAFT+Delphi+ISO Overview of the DELPHI Program The Advanced Research Projects Agency for Health (ARPA-H) has released a Draft Innovative Solutions Opening (ISO) for the Delphi program through its Resilient Systems Office (RSO). The draft announcement, ARPA-H-SOL-26-153, is intended to inform the research community about an upcoming funding opportunity and allow potential performers time to prepare
ARPA-H’s Delphi Program Draft ISO Signals New Opportunities in Continuous Biosensing Read More »
